Using the JAK pathway inhibitor ruxolitinib to inhibit IL6/STAT3 signaling disrupts the ER-FOXA1-pSTAT3 enhancer-driven transcriptional program of target genes in breast cancer and suppresses the invasive capacity of cancer cells [301]. Here, FOXA1 is linked to cancer.